A new β-tricalcium phosphate with uniform triple superporous structure as a filling material after curettage of bone tumor.
A new β-tricalcium phosphate with uniform triple superpore structure, SuperPore(®) (HOYA, Tokyo, Japan), has been in clinical use since 2010. As far as we are aware of, there have been no reported clinical studies using this material. We report on the first clinical cases of benign bone tumor filled with SuperPore(®). We retrospectively evaluated the results for 34 benign bone tumors treated by curettage followed by implantation of the highly purified β-tricalcium phosphates Osferion(®) (Olympus, Tokyo, Japan) or SuperPore(®). After a mean follow-up of 12 months, none of the patients experienced local recurrence of the tumor or any adverse effects from the filling materials. Radiographically, complete resorption of the material and bone remodeling were achieved in 32 cases. In 17 selected cases with a small bone tumor, the mean period for complete resorption of the filling material was 21 weeks in the Osferion(®) group and 15 weeks in the SuperPore(®) group, with the latter showing a trend for better outcomes. SuperPore(®) is a safe and reliable filling substitute for defects following curettage of small bone tumors. Both SuperPore(®) and Osferion(®) gave satisfactory results with good biocompatibility and fast resorption characteristics.